| 4.03 -0.22 (-5.18%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.5 | 1-year : | 6.42 |
| Resists | First : | 4.71 | Second : | 5.5 |
| Pivot price | 4.15  |
|||
| Supports | First : | 3.84 | Second : | 3.3 |
| MAs | MA(5) : | 4.3 |
MA(20) : | 4.05 |
| MA(100) : | 4.22 |
MA(250) : | 3.83 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 61.9 |
D(3) : | 71.3 |
| RSI | RSI(14): 49.9 |
|||
| 52-week | High : | 12.14 | Low : | 1.41 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EVAX ] has closed above bottom band by 35.8%. Bollinger Bands are 36.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.28 - 4.3 | 4.3 - 4.32 |
| Low: | 3.87 - 3.9 | 3.9 - 3.93 |
| Close: | 3.99 - 4.04 | 4.04 - 4.07 |
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Fri, 24 Apr 2026
Evaxion Biotech A/s Stock Price Forecast. Should You Buy EVAX? - StockInvest.us
Fri, 17 Oct 2025
Evaxion reports 75% response rate in melanoma vaccine trial - Investing.com
Wed, 15 Oct 2025
Evaxion shares spike as AI-designed melanoma vaccine data hits market - Mugglehead Investment Magazine
Thu, 25 Sep 2025
Evaxion Stock Climbs Amid Biotech Surge - StocksToTrade
Mon, 26 May 2025
Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025 (NASDAQ:EVAX) - Seeking Alpha
Tue, 13 May 2025
EVAX Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 282 (M) |
| Held by Insiders | 17.4 (%) |
| Held by Institutions | 7.3 (%) |
| Shares Short | 38 (K) |
| Shares Short P.Month | 53 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.03 |
| Profit Margin | -102.4 % |
| Operating Margin | -122.7 % |
| Return on Assets (ttm) | -28.3 % |
| Return on Equity (ttm) | -100.2 % |
| Qtrly Rev. Growth | -100 % |
| Gross Profit (p.s.) | 0.9 |
| Sales Per Share | 0.9 |
| EBITDA (p.s.) | -1.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -4.04 |
| PEG Ratio | 0 |
| Price to Book value | 1.97 |
| Price to Sales | 4.46 |
| Price to Cash Flow | -5.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|